Etamivan

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:09, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Etamivan
Clinical data
Trade namesAnalepticon
ATC code
Identifiers
  • N,N-Diethyl-4-hydroxy-3-methoxybenzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.005.599 Edit this at Wikidata
Chemical and physical data
FormulaC12H17NO3
Molar mass223.272 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)C1=CC(=C(C=C1)O)OC
  • InChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3 ☒N
  • Key:BQJODPIMMWWMFC-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Etamivan (INN, or ethamivan (USAN); trade names Analepticon and Vandid) is a respiratory stimulant drug[1] related to nikethamide. It was mainly used in the treatment of barbiturate overdose[2] and chronic obstructive pulmonary disease,[3] but has now largely fallen into disuse.

References

  1. ^ Hirsh K, Wang SC. Respiratory stimulant effects of ethamivan and picrotoxin. Journal of Pharmacology and Experimental Therapeutics. 1975 May;193(2):657-63.
  2. ^ Wheeldon PJ, Perry AW. The use of ethamivan in the treatment of barbiturate poisoning. Canadian Medical Association Journal. 1963 Jul 6;89:20-2.
  3. ^ Sproule BJ, Jans RL, Breitkreutz H, Mahon W. Effects of ethamivan in patients with chronic respiratory disease. Canadian Medical Association Journal. 1964 Dec 5;91:1203-8.